Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$551.22
-1.6%
$580.69
$428.97
$678.21
$34.20B0.39327,359 shs1.50 million shs
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$106.47
-0.2%
$102.89
$76.53
$131.49
$25.65B1.29941,150 shs367,468 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$110.87
+0.2%
$106.53
$66.01
$119.96
$137.67B0.297.68 million shs6.60 million shs
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$71.64
-1.0%
$69.39
$53.95
$75.99
$33.87B0.9219,678 shs8,021 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
0.00%+3.32%-2.88%-5.36%+30.25%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%+0.18%+11.50%+17.20%+32.80%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.00%+2.00%+0.29%-1.23%+61.30%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.00%-0.43%+2.09%+23.97%+18.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenex SE stock logo
ARGX
argenex
4.3107 of 5 stars
4.53.00.00.02.71.72.5
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.4678 of 5 stars
4.42.00.00.01.90.80.0
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.8171 of 5 stars
1.43.04.24.14.02.53.1
Novozymes A/S stock logo
NVZMY
Novozymes A/S
1.6045 of 5 stars
0.03.02.50.00.00.02.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
3.05
Buy$729.9332.42% Upside
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.83
Moderate Buy$137.8629.48% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.78
Moderate Buy$110.55-0.29% Downside
Novozymes A/S stock logo
NVZMY
Novozymes A/S
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest NVZMY, GILD, ARGX, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$138.00
6/24/2025
argenex SE stock logo
ARGX
argenex
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00
6/16/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$145.00 ➝ $138.00
6/11/2025
argenex SE stock logo
ARGX
argenex
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00
6/10/2025
argenex SE stock logo
ARGX
argenex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$720.00
6/5/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$134.00 ➝ $145.00
6/3/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$151.00 ➝ $155.00
6/2/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$112.00
5/29/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Neutral$110.00
5/22/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$120.00 ➝ $116.00
5/22/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$134.00 ➝ $134.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$2.25B14.95$2.92 per share188.57$90.49 per share6.09
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$2.98B8.60N/AN/A$87.61 per share1.22
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$28.75B4.80$6.88 per share16.11$15.44 per share7.18
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$4.15B8.09$1.84 per share38.95$25.82 per share2.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$833.04M$16.2134.0050.801.0140.20%16.15%14.33%7/24/2025 (Estimated)
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$719.92M-$3.40N/AN/AN/A-27.37%-3.94%-3.41%8/4/2025 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$480M$4.7523.3413.670.7220.76%51.93%17.40%8/6/2025 (Estimated)
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$330.91M$1.5845.3433.481.37N/AN/AN/A8/21/2025 (Estimated)

Latest NVZMY, GILD, ARGX, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
argenex SE stock logo
ARGX
argenex
$2.87N/AN/AN/A$776.82 millionN/A
5/8/2025Q1 2025
argenex SE stock logo
ARGX
argenex
$2.32$2.58+$0.26$2.58$748.34 million$1.35 billion
4/24/2025Q1 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.77$1.81+$0.04$1.04$6.77 billion$6.67 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.162.85%N/A66.53%10 Years
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$0.761.06%N/A48.10%N/A

Latest NVZMY, GILD, ARGX, and BNTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.793%6/13/20256/13/20256/27/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
7.29
6.68
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
10.18
10.02
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.16
1.37
1.23
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.14
1.73
1.06

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.03%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.27%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,59961.06 million59.58 millionOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
6,772240.39 million194.24 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,6001.24 billion1.24 billionOptionable
Novozymes A/S stock logo
NVZMY
Novozymes A/S
10,582468.30 millionN/ANot Optionable

Recent News About These Companies

NVZMY Novozymes A/S - Seeking Alpha
Novonesis A/S (NVZMY)
Best Income Stocks to Buy for May 14th
New Strong Buy Stocks for May 14th
Novonesis price target lowered to DKK 490 from DKK 500 at Barclays
Invitation to the Annual General Meeting
Novonesis (Novozymes) B ADR
Novonesis: Still Too Expensive
Novonesis added to European Conviction List at Goldman Sachs

New MarketBeat Followers Over Time

Media Sentiment Over Time

argenex stock logo

argenex NASDAQ:ARGX

$551.22 -8.92 (-1.59%)
As of 04:00 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$106.47 -0.25 (-0.23%)
As of 04:00 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$110.87 +0.20 (+0.18%)
As of 04:00 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Novozymes A/S stock logo

Novozymes A/S OTCMKTS:NVZMY

$71.64 -0.69 (-0.95%)
As of 03:59 PM Eastern

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.